Central nervous system relapse in diffuse large B lymphoma: a retrospective cohort study: CNS relapse in LDCGB

Mostrar todas las versiones(2)

Introduction: CNS relapse in patients with LDCGB is a poor prognosis event. The incidence of relapse is variable according to the literature. Data in Latin America is lacking. Methods: In order to establish the incidence of CNS relapse in our cohort, time to CNS relapse and the impact of CNS relapse...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Warley, Fernando, Cristaldo, Nancy, Colucci, Giuliana, Otero, Victoria
Formato: Artículo revista
Lenguaje:Español
Publicado: Universidad Nacional Cba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2021
Materias:
lymphoma, non-hodgkin
lymphoma, large b-cell, diffuse
neoplasm recurrence, local
linfoma no hodgkin
recurrencia local de neoplasia
sistema nervioso central
Linfoma de Células B Grandes Difuso
linfoma não-hodgkin
linfoma difuso de grandes células b
recidiva local de neoplasia
sistema nervoso central
Acceso en línea:https://revistas.unc.edu.ar/index.php/med/article/view/28183
Aporte de:
Revistas de la UNC de Universidad Nacional de Córdoba
id I10-R10-article-28183
record_format ojs
institution Universidad Nacional de Córdoba
institution_str I-10
repository_str R-10
container_title_str Revistas de la UNC
language Español
format Artículo revista
topic lymphoma, non-hodgkin
lymphoma, large b-cell, diffuse
neoplasm recurrence, local
linfoma no hodgkin
recurrencia local de neoplasia
sistema nervioso central
Linfoma de Células B Grandes Difuso
linfoma não-hodgkin
linfoma difuso de grandes células b
recidiva local de neoplasia
sistema nervoso central
spellingShingle lymphoma, non-hodgkin
lymphoma, large b-cell, diffuse
neoplasm recurrence, local
linfoma no hodgkin
recurrencia local de neoplasia
sistema nervioso central
Linfoma de Células B Grandes Difuso
linfoma não-hodgkin
linfoma difuso de grandes células b
recidiva local de neoplasia
sistema nervoso central
Warley, Fernando
Cristaldo, Nancy
Colucci, Giuliana
Otero, Victoria
Central nervous system relapse in diffuse large B lymphoma: a retrospective cohort study: CNS relapse in LDCGB
topic_facet lymphoma, non-hodgkin
lymphoma, large b-cell, diffuse
neoplasm recurrence, local
linfoma no hodgkin
recurrencia local de neoplasia
sistema nervioso central
Linfoma de Células B Grandes Difuso
linfoma não-hodgkin
linfoma difuso de grandes células b
recidiva local de neoplasia
sistema nervoso central
author Warley, Fernando
Cristaldo, Nancy
Colucci, Giuliana
Otero, Victoria
author_facet Warley, Fernando
Cristaldo, Nancy
Colucci, Giuliana
Otero, Victoria
author_sort Warley, Fernando
title Central nervous system relapse in diffuse large B lymphoma: a retrospective cohort study: CNS relapse in LDCGB
title_short Central nervous system relapse in diffuse large B lymphoma: a retrospective cohort study: CNS relapse in LDCGB
title_full Central nervous system relapse in diffuse large B lymphoma: a retrospective cohort study: CNS relapse in LDCGB
title_fullStr Central nervous system relapse in diffuse large B lymphoma: a retrospective cohort study: CNS relapse in LDCGB
title_full_unstemmed Central nervous system relapse in diffuse large B lymphoma: a retrospective cohort study: CNS relapse in LDCGB
title_sort central nervous system relapse in diffuse large b lymphoma: a retrospective cohort study: cns relapse in ldcgb
description Introduction: CNS relapse in patients with LDCGB is a poor prognosis event. The incidence of relapse is variable according to the literature. Data in Latin America is lacking. Methods: In order to establish the incidence of CNS relapse in our cohort, time to CNS relapse and the impact of CNS relapse risk factors, a retrospective cohort study was performed, from January 2012 to June 2017. Results: One hundred and forty seven patients were analyzed. The median age was 66 years (ICR 56-76); 76 patients (51.70%) were men. The IPI was low or intermediate/low in 115 (78.2%) cases. The CNS IPI was intermediate in 77 (52.4%) and high in 14 (9.5%) of cases. Thirty-five (23.81%) patients received intrathecal prophylaxis. No patient received systemic prophylaxis. During the follow-up, 8 (4.59%) patients had CNS relapse, none of them with high IPI. The median time to relapse was 6.5 months (ICR 5.5-10). Seven (87.5%) patients relapsed within the year of diagnosis. We found no risk factors for CNS involvement in the bivariate analysis. The incidence of relapse was 2.7% (CI 0.2% -4.6%), 4.8% (CI 1.8% -8.9%) and 5.4% (CI 4.5- 8.9%) at 6, 12 and 24 months, respectively. Discussion: The incidence of CNS relapse was similar to that described in the international series. Our study confirms that the majority of patients relapse during the first year of follow up. We must carry out broader collaborative work to better establish the risk factor for CNS relapse.
publisher Universidad Nacional Cba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
publishDate 2021
url https://revistas.unc.edu.ar/index.php/med/article/view/28183
work_keys_str_mv AT warleyfernando centralnervoussystemrelapseindiffuselargeblymphomaaretrospectivecohortstudycnsrelapseinldcgb
AT cristaldonancy centralnervoussystemrelapseindiffuselargeblymphomaaretrospectivecohortstudycnsrelapseinldcgb
AT coluccigiuliana centralnervoussystemrelapseindiffuselargeblymphomaaretrospectivecohortstudycnsrelapseinldcgb
AT oterovictoria centralnervoussystemrelapseindiffuselargeblymphomaaretrospectivecohortstudycnsrelapseinldcgb
AT warleyfernando recaidaensistemanerviosocentralenlinfomadifusodecelulasbgrandesestudiodecohorteretrospectivarecaidaensncenldcbg
AT cristaldonancy recaidaensistemanerviosocentralenlinfomadifusodecelulasbgrandesestudiodecohorteretrospectivarecaidaensncenldcbg
AT coluccigiuliana recaidaensistemanerviosocentralenlinfomadifusodecelulasbgrandesestudiodecohorteretrospectivarecaidaensncenldcbg
AT oterovictoria recaidaensistemanerviosocentralenlinfomadifusodecelulasbgrandesestudiodecohorteretrospectivarecaidaensncenldcbg
AT warleyfernando recaidadosistemanervosocentralnolinfomadifusodegrandescelulasbestudodecoorteretrospectivorecaidadosncnoldgcb
AT cristaldonancy recaidadosistemanervosocentralnolinfomadifusodegrandescelulasbestudodecoorteretrospectivorecaidadosncnoldgcb
AT coluccigiuliana recaidadosistemanervosocentralnolinfomadifusodegrandescelulasbestudodecoorteretrospectivorecaidadosncnoldgcb
AT oterovictoria recaidadosistemanervosocentralnolinfomadifusodegrandescelulasbestudodecoorteretrospectivorecaidadosncnoldgcb
first_indexed 2022-08-20T01:27:25Z
last_indexed 2022-08-20T01:27:25Z
_version_ 1770719067795095552
spelling I10-R10-article-281832021-12-29T20:15:49Z Central nervous system relapse in diffuse large B lymphoma: a retrospective cohort study: CNS relapse in LDCGB Recaída en sistema nervioso central en linfoma difuso de células B grandes: estudio de cohorte retrospectiva: Recaída en SNC en LDCBG Recaída do sistema nervoso central no linfoma difuso de grandes células B: estudo de coorte retrospectivo: Recaída do SNC no LDGCB Warley, Fernando Cristaldo, Nancy Colucci, Giuliana Otero, Victoria lymphoma, non-hodgkin lymphoma, large b-cell, diffuse neoplasm recurrence, local linfoma no hodgkin recurrencia local de neoplasia sistema nervioso central Linfoma de Células B Grandes Difuso linfoma não-hodgkin linfoma difuso de grandes células b recidiva local de neoplasia sistema nervoso central Introduction: CNS relapse in patients with LDCGB is a poor prognosis event. The incidence of relapse is variable according to the literature. Data in Latin America is lacking. Methods: In order to establish the incidence of CNS relapse in our cohort, time to CNS relapse and the impact of CNS relapse risk factors, a retrospective cohort study was performed, from January 2012 to June 2017. Results: One hundred and forty seven patients were analyzed. The median age was 66 years (ICR 56-76); 76 patients (51.70%) were men. The IPI was low or intermediate/low in 115 (78.2%) cases. The CNS IPI was intermediate in 77 (52.4%) and high in 14 (9.5%) of cases. Thirty-five (23.81%) patients received intrathecal prophylaxis. No patient received systemic prophylaxis. During the follow-up, 8 (4.59%) patients had CNS relapse, none of them with high IPI. The median time to relapse was 6.5 months (ICR 5.5-10). Seven (87.5%) patients relapsed within the year of diagnosis. We found no risk factors for CNS involvement in the bivariate analysis. The incidence of relapse was 2.7% (CI 0.2% -4.6%), 4.8% (CI 1.8% -8.9%) and 5.4% (CI 4.5- 8.9%) at 6, 12 and 24 months, respectively. Discussion: The incidence of CNS relapse was similar to that described in the international series. Our study confirms that the majority of patients relapse during the first year of follow up. We must carry out broader collaborative work to better establish the risk factor for CNS relapse. Introducción: La recaída del SNC en pacientes con LDCBG en un evento de mal pronóstico. La incidencia de recaída  es variable según la bibliografía. Los datos en América Latina son escasos. Metodología: Para establecer la incidencia de recaída en SNC, el tiempo a la recaída en SNC y el impacto de los factores de riesgo de recaída del SNC, se realizó un estudio de cohorte retrospectiva, de enero del 2012 a junio del 2017.  Resultados: Se analizaron 147 pacientes. La mediana de edad fue de 66 años (IIC 56-76); 76 pacientes (51,70%) fueron hombres. El IPI fue bajo o intermedio/bajo en 115 (78,2%) casos. El CNS IPI fue intermedio en 77 (52,4%) y alto en 14 (9,5%) casos. Treinta y cinco (23.81%) pacientes recibieron profilaxis intratecal del SNC, ninguno profilaxis sistémica. Durante el seguimiento, 8 (4,59%) pacientes tuvieron recaída del SNC. La mediana de tiempo a la recaída fue de 6,5 meses (IIC 5,5 - 10). Siete (87,5%) pacientes recayeron dentro del año. No encontramos factores de riesgo para el compromiso del SNC en el análisis bivariado. La incidencia de recaída fue del 2,7% (IC 0,2%-4,6%), 4,8% (IC 1,8%-8,9%) y 5,4% (IC 4,5-8,9%) a los 6, 12 y 24 meses, respectivamente. Discusión: La incidencia de recaída del SNC fue similar a la descrita en las series internacionales. Nuestro estudio confirma que la mayoría de los pacientes que recaen, lo hacen dentro del primer año del diagnóstico. Debemos realizar trabajos colaborativos más amplios para establecer mejor factores de riesgo asociados. Introdução: recidiva do SNC em pacientes com LDGCB em um evento de mau prognóstico. A incidência de recidiva é variável de acordo com a literatura. Os dados na América Latina são escassos. Métodos: Para estabelecer a incidência de recidiva do SNC em nossa coorte, o tempo até a recidiva no SNC e o impacto dos fatores de risco de recaída no SNC, foi realizado um estudo de coorte retrospectivo, de janeiro de 2012 a junho de 2017. Resultados: Cento e quarenta e sete pacientes foram analisados. A idade média foi de 66 anos (IIQ 56-76); 76 pacientes (51,70%) eram homens. O IPI foi baixo ou intermediário / baixo em 115 (78,2%) casos. O IPI do CNS foi intermediário em 77 (52,4%) e alto em 14 (9,5%) casos. Trinta e cinco (23,81%) pacientes receberam profilaxia intratecal no SNC, nenhuma profilaxia sistêmica. Durante o seguimento, 8 (4,59%) pacientes tiveram recidiva no SNC. O tempo médio para recidiva foi de 6,5 meses (IIQ 5.5-10). Sete (87,5%) pacientes recidivaram em um ano. Não encontramos fatores de risco para o envolvimento do SNC na análise bivariada. A incidência de recidiva foi de 2,7% (IC 0,2% -4,6%), 4,8% (IC 1,8% -8,9%) e 5,4% (IC 4,5- 8,9%) aos 6, 12 e 24 meses, respectivamente. Discussão: A incidência de recidiva no SNC foi semelhante à descrita na série internacional. Nosso estudo confirma que a maioria dos pacientes com recidiva o faz no primeiro ano de diagnóstico. Devemos realizar um trabalho colaborativo mais amplo para melhor estabelecer os fatores de risco associados. Universidad Nacional Cba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2021-06-28 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion application/pdf text/html https://revistas.unc.edu.ar/index.php/med/article/view/28183 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 78 No. 2 (2021); 142-146 Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 78 Núm. 2 (2021); 142-146 Revista da Faculdade de Ciências Médicas de Córdoba; v. 78 n. 2 (2021); 142-146 1853-0605 0014-6722 10.31053/1853.0605.v78.n2 spa https://revistas.unc.edu.ar/index.php/med/article/view/28183/33669 https://revistas.unc.edu.ar/index.php/med/article/view/28183/33670 Derechos de autor 2021 Universidad Nacional de Córdoba http://creativecommons.org/licenses/by-nc/4.0

Ejemplares similares